Ovid Therapeutics rounds out a trio of biotech companies that went public this week — but unlike its compatriots, its $75 million IPO performed more weakly than expected.
The company, which is developing drugs for patients with rare neurological disorders, opened trading at $15. But by market close, that fell 18 percent to $12.25 per share.
About the Author Reprints
